The recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models, according to new research published in the Journal of American College of Cardiology. Their study also shows that this drug can make the heart produce more energy and function more efficiently. ‘This drug could be a promising
The recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models, according to new research published in the Journal of American College of Cardiology. Their study also shows that this drug can make the heart produce more energy and function more efficiently.
‘This drug could be a promising treatment for heart failure in both non-diabetic and diabetic patients,’ said the study’s lead author Juan Badimon. ‘Our research can lead to a potential application in humans, save lives, and improve quality of life.’
Empagliflozin limits renal sugar resorption and is the first drug in the history of type 2 diabetes proven to prolong survival. While diabetes patients are typically at higher risk of heart failure, past studies have suggested that those who take empagliflozin don’t commonly develop heart failure. Those observations led a team of researchers to question if the drug contains a mechanism, independent of anti-diabetic activity that is linked to heart failure prevention, and whether it could have the same impact on non-diabetics.
Investigators from the Atherothrombosis Research Unit tested the hypothesis by inducing heart failure in 14 non-diabetic pigs. For two months, they treated half of the animals with empagliflozin and the other group with a placebo. The team evaluated the pigs with cardiac magnetic resonance, 3D-echocardiography, and invasive catheterization at three different points in the study (before inducing, one day after inducing, and at the two-month mark). At two months, all animals in the group treated with empagliflozin experienced improved heart function. Specifically, those pigs had less water accumulation in the lungs (less pulmonary congestion, which is responsible for causing shortness of breath) and lower levels of biomarkers of heart failure. Importantly, the left ventricles had stronger contractions (enhanced systolic function), got smaller (less dilated), and were less thick (less hypertrophy), and the heart was a normal shape (less architectural remodeling).
The researchers also found that the drug addressed heart failure by improving cardiac metabolism. The hearts of pigs on the medication were consuming more fatty acids and ketone bodies (three related compounds–acetone, acetoacetic acid, and beta-hydroxybutyric acid–produced during the metabolism of fats) and less glucose, as contrasted with heart failure patients (diabetic and non-diabetic), whose hearts consume more glucose and almost no fatty acids and produces less energy. This boost in metabolism helped the hearts produce more energy and function more strongly and efficiently.
The authors are currently studying whether empagliflozin is an effective heart failure treatment in non-diabetic human patients in the EMPATROPISM clinical trial.